Ni X,Song Q,Cassady K,et al. PD-L1 interacts with CD80 to regulate graftversus-leukemia activity of donor CD8 + T cells[J]. J Clin Invest,2017,127( 5) : 1960. TAO LL,LAI X,WEI J.PD -1 /PD -L signaling pathway in chronic hepatitis B[J].J Clin Hepatol,2016,32( 12) : 237...
3. Hashem O A., et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Frontiers in Pharmacology. 2017, 8: 1-15.
3. Wu Q, Jiang L, Li SC, et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin. 2021, 42(1): 1-9. doi: 10.1038/s41401-020-0366-x. 4. 中国抗癌协会肿瘤病理专业委员会,中国临床肿瘤...
4.Wu, Q., Jiang, L., Li, Sc. et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin 42, 1–9 (2021). 5.Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, et al. Structure of the complex of human programmed death 1, P...
[13].Qian Wu, Li Jiang, Si-Cheng Li, et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin. 2021 Jan;42(1):1-9. [14].Julia A Beaver, Richard Pazdur. The Wild West of Chec...
3. Hashem O A., et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Frontiers in Pharmacology. 2017, 8: 1-15.
5.Wu, Q., Jiang, L., Li, Sc. et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin 42, 1–9 (2021). 6.田季平, 张剑, 周金培,等. 中国药科大学学报, 2019. 7.黄坤. PD-1/PD-L1小分子免疫抑制剂的设计,合成及活性筛选. ...
Smallmolecule inhibitors targeting the PD-1/PD-L1 signaling pathway. ActaPharmacologica Sinica (2020) 0:1–9; https://doi.org/10.1038/s41401-020-0366-x CA-170– A Potent Small-Molecule PD-L1 Inhibitor or Not? Molecules 2019, 24, 2804;doi:10.3390/molecules24152804 ...
PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling[J]....
Bidirectional regulation between EMT and PD-L1 signaling is discussed in terms of cancer immune escape and possible combined therapies. Additionally, we investigated the value of preclinical or clinical trials using EMT targeted therapy combined with PD-L1 inhibitors. This review may help to further ...